These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12622760)

  • 1. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.
    Caprilli R; Cottone M; Tonelli F; Sturniolo G; Castiglione F; Annese V; Papi C; Viscido A; Cammà C; Corrao G; Latella G
    Aliment Pharmacol Ther; 2003 Feb; 17(4):517-23. PubMed ID: 12622760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
    Reinisch W; Angelberger S; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Teml A; Schaeffeler E; Schwab M; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR;
    Gut; 2010 Jun; 59(6):752-9. PubMed ID: 20551460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC).
    Caprilli R; Andreoli A; Capurso L; Corrao G; D'Albasio G; Gioieni A; Assuero Lanfranchi G; Paladini I; Pallone F; Ponti V
    Aliment Pharmacol Ther; 1994 Feb; 8(1):35-43. PubMed ID: 8186345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto.
    Frieri G; Pimpo MT; Andreoli A; Annese V; Comberlato M; Corrao G; Palumbo G; Sturniolo GC; Tonelli F; Caprilli R
    Aliment Pharmacol Ther; 1999 May; 13(5):577-82. PubMed ID: 10233180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
    Hanauer SB; Korelitz BI; Rutgeerts P; Peppercorn MA; Thisted RA; Cohen RD; Present DH
    Gastroenterology; 2004 Sep; 127(3):723-9. PubMed ID: 15362027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group.
    Ewe K; Böttger T; Buhr HJ; Ecker KW; Otto HF
    Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):277-82. PubMed ID: 10333200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
    Prakash A; Markham A
    Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for prevention of post-operative recurrence of Crohn's disease.
    Doherty G; Bennett G; Patil S; Cheifetz A; Moss AC
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006873. PubMed ID: 19821389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group.
    Brignola C; Cottone M; Pera A; Ardizzone S; Scribano ML; De Franchis R; D'Arienzo A; D'Albasio G; Pennestri D
    Gastroenterology; 1995 Feb; 108(2):345-9. PubMed ID: 7835575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.
    Fedorak RN; Feagan BG; Hotte N; Leddin D; Dieleman LA; Petrunia DM; Enns R; Bitton A; Chiba N; Paré P; Rostom A; Marshall J; Depew W; Bernstein CN; Panaccione R; Aumais G; Steinhart AH; Cockeram A; Bailey RJ; Gionchetti P; Wong C; Madsen K
    Clin Gastroenterol Hepatol; 2015 May; 13(5):928-35.e2. PubMed ID: 25460016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease.
    McLeod RS; Wolff BG; Steinhart AH; Carryer PW; O'Rourke K; Andrews DF; Blair JE; Cangemi JR; Cohen Z; Cullen JB
    Gastroenterology; 1995 Aug; 109(2):404-13. PubMed ID: 7615189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study.
    Zabana Y; Mañosa M; Cabré E; Bernal I; Marín L; Lorenzo-Zúñiga V; Moreno V; Boix J; Domènech E
    J Gastroenterol Hepatol; 2014; 29(7):1413-7. PubMed ID: 24627958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine.
    Ren J; Wu X; Liao N; Wang G; Fan C; Liu S; Ren H; Zhao Y; Li J
    J Int Med Res; 2013 Feb; 41(1):176-87. PubMed ID: 23569144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.
    Mowat C; Arnott I; Cahill A; Smith M; Ahmad T; Subramanian S; Travis S; Morris J; Hamlin J; Dhar A; Nwokolo C; Edwards C; Creed T; Bloom S; Yousif M; Thomas L; Campbell S; Lewis SJ; Sebastian S; Sen S; Lal S; Hawkey C; Murray C; Cummings F; Goh J; Lindsay JO; Arebi N; Potts L; McKinley AJ; Thomson JM; Todd JA; Collie M; Dunlop MG; Mowat A; Gaya DR; Winter J; Naismith GD; Ennis H; Keerie C; Lewis S; Prescott RJ; Kennedy NA; Satsangi J;
    Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):273-282. PubMed ID: 28404197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.
    Allocca M; Landi R; Bonovas S; Fiorino G; Papa A; Spinelli A; Furfaro F; Peyrin-Biroulet L; Armuzzi A; Danese S
    Digestion; 2017; 96(3):166-172. PubMed ID: 28903094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
    Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
    Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.